The extracellular receptor domain of p95-HER2 is proteolytically cleaved and thereby lacks the trastuzumab binding site, which makes this receptor inert to trastuzumab. High p95-HER2 expression is ...

As a DNA alkylator, rather than a tubulin-binding drug, it isn’t reliant ... the so-called bystander effect.” [vic-]trastuzumab duocarmazine is in a pivotal phase 3 clinical trial for ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).